Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D²EFT: Dolutegravir-based Second-line ART in HIV-1
NCT03017872Phase 4Unknown
- Sponsor
- The Kirby Institute
- Start
- Nov 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 4 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by The Kirby Institute. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03017872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017872.